Cumberland Pharmaceuticals (CPIX) Q1 2025 earnings summary

Executive summary

• Achieved $11.7 million in Q1 2025 revenue, a 38% year-over-year increase, driven by portfolio growth and a $3 million milestone from Vibativ's China approval.

• Net profit reached $1.3 million, with adjusted earnings of $2.4 million and $3.9 million in operating cash flow.

• Positive top-line results from phase II Ifetroban study in Duchenne muscular dystrophy (DMD) patients, marking a breakthrough in cardiac complication treatment.

• Vibativ received regulatory approval in China, with launch expected by year-end, expanding access to a major pharmaceutical market.

• The company focuses on specialty pharmaceuticals in hospital acute care, gastroenterology, and oncology, with six FDA-approved products and ongoing clinical development programs.

Financial highlights

• Q1 2025 net revenue: $11.7 million, up $3.2 million (38%) year-over-year.

• Product revenue breakdown: Kristalose $3.5M, Sancuso $2.3M, Vibativ $1.4M, Caldolor $1.3M.

• Net income: $1.3 million; adjusted earnings: $2.4 million (16 cents/share); operating income: $1.29 million, reversing a prior year loss.

• Cash and cash equivalents at quarter-end: $15.1 million; total assets: $69.9 million; equity: $28.7 million.

• Cash flow from operations was $3.9 million; net cash decreased by $2.9 million due to financing and investing outflows.

Outlook and guidance

• Anticipates continued momentum across approved brands, expanded international partnerships, and further clinical pipeline progress.

• Expects Vibativ launch in China later in 2025 following regulatory approval.

• Plans to announce top-line results from systemic sclerosis study and prepare for end-of-Phase-II FDA meeting for ifetroban in DMD.

• The company anticipates minimal income tax payments in 2025 and beyond due to $52.7 million in federal net operating loss carryforwards.